Acadia Pharmaceuticals Inc (NASDAQ: ACAD)

Sector: Healthcare Industry: Biotechnology CIK: 0001070494
P/B 4.92
P/E 17.29
P/S 4.31
Market Cap 4.52 Bn
ROIC (Qtr) 42.44
Div Yield % 0.00
Rev 1y % (Qtr) 11.27
Total Debt (Qtr) 43.03 Mn
Debt/Equity (Qtr) 0.05

About

Stock Price Chart

Analysis

Pros

  • Strong operating cash flow of 198.95M provides robust 4.62x coverage of total debt 43.03M, indicating excellent debt servicing capability and financial flexibility.
  • Strong tangible asset base of 1.22B provides 28.34x coverage of total debt 43.03M, indicating robust asset backing and low credit risk.
  • Robust free cash flow of 197.81M exceeds capital expenditure of 1.14M by 173.82x, indicating strong organic growth funding capability.
  • Short-term investments of 589.02M provide solid 1.76x coverage of other current liabilities 334.84M, indicating strong liquidity.
  • Operating cash flow of 198.95M fully covers other non-current liabilities 13.89M by 14.32x, showing strong long-term stability.

Cons

  • Operating cash flow of 198.95M barely covers its investment activities of (124.55M), with a coverage ratio of -1.60, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (124.55M) provide weak support for R&D spending of 344.78M, which is -0.36x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of 198.95M shows concerning coverage of stock compensation expenses of 49.35M, with a 4.03 ratio indicating potential earnings quality issues.
  • Operating cash flow of 198.95M barely covers operating expenses of (146.51M) with a -1.36 ratio, suggesting thin operational efficiency margins and limited flexibility.
  • Retained earnings of (2.09B) provide limited buffer against comprehensive income items of 989000, which is -2110.17x, indicating elevated exposure to market risks.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 3.23 12.31
EV to Cash from Ops. 21.60 23.25
EV to Debt 99.89 738.44
EV to EBIT 15.70 -9.16
EV to EBITDA 16.86 6.95
EV to Free Cash Flow [EV/FCF] 21.73 21.90
EV to Market Cap 0.95 65.67
EV to Revenue 4.10 227.32
Price to Book Value [P/B] 4.92 22.34
Price to Earnings [P/E] 17.29 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -1,525.71 -27.13
Cash and Equivalents Growth (1y) % 63.17 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 103.24 -46.93
EBITDA Growth (1y) % 104.73 -1.68
EBIT Growth (1y) % 100.21 -56.45
EBT Growth (1y) % 100.21 -12.70
EPS Growth (1y) % 101.28 -28.31
FCF Growth (1y) % -2.39 -31.90
Gross Profit Growth (1y) % 13.07 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.79 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 0.75 3.85
Current Ratio 3.02 7.27
Debt to Equity Ratio 0.05 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 27.50 -18,234.31
EBIT Margin % 26.14 -18,580.80
EBT Margin % 26.14 -19,488.74
Gross Margin % 91.90 -7.59
Net Profit Margin % 24.90 -19,439.22